Skip to main content

Change in PDL Status for Stimulants and Related Agents Drug Class Effective August 18, 2025

Last updated on

Effective August 18, 2025, the Texas Health and Human Services Commission (HHSC) has removed the non-preferred status from certain methylphenidate products on the preferred drug list (PDL).

This change is the result of active national drug shortages on various brand-name and generic methylphenidate products.

HHSC has removed the non-preferred status from the following drugs:

National Drug Code (NDC)Drug Name
70165010030Cotempla XR-ODT 8.6 mg tablet
70165020030Cotempla XR-ODT 17.3 mg tablet
70165030030Cotempla XR-ODT 25.9 mg tablet
24478007401Quillichew ER 20 mg chew tablet
24478007501Quillichew ER 30 mg chew tablet
24478007601Quillichew ER 40 mg chew tablet
10702007501Methylphenidate ER 10 mg tablet
10702007601Methylphenidate ER 20 mg tablet

These changes allow providers to prescribe certain methylphenidate products without requiring a PDL prior authorization. This helps ensure that clients can continue to access essential medications.

Email vdp-formulary@hhsc.state.tx.us with any questions.